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Background: Most Cardiomyopathies are inherited diseases with auto-
somal dominant inheritance and delayed cardiac expression. In families with
a documented causal mutation, predictive genetic testing can be proposed to
“healthy” relatives to appropriately manage medical follow-up. Psychological
impact of predictive genetic testing is however poorly described in these
diseases.
Aim and methods: We performed a prospective study about the psycho-
logical impact of predictive genetic testing in adults seen in our out-patient
multidisciplinary consultation (cardiologist, genetic counsellor, and psycho-
logist). Self-report questionnaires were proposed during the initial consultation
(Q1) and 1 to 3 month after genetic result was given (Q2). Questionnaires
used validated scales to evaluate anxiety, depression, hopelessness, self-
esteem, impact of announcement, quality of life (QOL), and motivations.
Results: Sixty-six adults completed questionnaire Q1 and 38 completed
questionnaire Q2 (15 mutation carriers, 23 non carriers). Analysis of psycho-
metric tests revealed no significant modification before/after genetic results.
However, genetic status influenced the level of general anxiety, depression
score and QOL. The consultation process was evaluated as useful (97%) and
reassuring (80%). The interview with the pyschologist was useful especially
for the anticipation of the result (73%). Waiting period (minimal period fixed
between consultation and blood sampling) was evaluated as reassuring (38%)
but unnecessary (91%).
Conclusion: We report on the first French evaluation of the psychological
impact of predictive genetic testing in cardiomyopathies. No deleterious effect
of genetic results was observed. However the study underlines the usefulness
of multidisciplinary management, especially to help the relatives to better
anticipate the genetic result and consequences.
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The clinical value of DDD pacing as primary treatment of HOCM remains
controversial. Very long-term data are lacking.
Aims: single-centre observational study aimed at describing the very long
term effects on symptoms, clinical and echocardiographic outcomes
Patients: 54 patients (59±14 years) with symptomatic (NYHA Class >2)
drug-refractory HOCM implanted with a DDD pacemaker with or without
defibrillator between 1991 and 2007 and followed up to 20 years (mean 11.5;
range 0,4-21,8).
Main results are summarised in table. No patient had myomectomy or
septal ablation during follow-up (f/u). NYHA functional class and other symp-
toms were significantly improved at 1-2 years and at the end of f/u. Left ven-
tricular outflow tract (LVOT) gradient decreased by a mean of 78% at 1-2
years and 89% at end f/u consistent with SAM resolution. LV ejection fraction
decreased over time with a mean value of 56% at end f/u without evidence of
cavity dilatation. The actuarial survival rate was 90% at 5-yrs and 65% at
10-yrs. 24 patients died, 19 from non cardiac cause and 5 cardiovascular.
2 patients had heart transplant after 8 and 13 yrs.
Conclusion: The clinical and echocardiographic outcome of HOCM
patients treated by DDD pacing seems favourable, inviting to re-evaluate the
exact value of the therapy in further controlled studies
Table – Main results
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Background: Transthyretin (TTR) familial amyloid polyneuropathy (FAP)
is a fatal autosomal dominant neurodegenerative disease characterized by
deposition of transthyretin targeting mainly the peripheral nervous system and
the heart. Early noninvasive detection of cardiac impairment is of importance
for the therapeutic management.
Aim: Assess if natriuretic peptide (NT-proBNP) or troponin T (cTnT) are
reliable biomarkers to predict echocardiographic left ventricle (LV) impair-
ment in a wide variety of TTR patients.
Methods: 36 asymptomatic carriers and patients with proven FAP genetic
mutation had clinical, biological and echocardiography assessment of left ven-
tricle (LV) systolic function (SD), filling pressure (FP) and hypertrophy
(LVH) as marker of amyloid deposition
Results: In the all cohort, the median (IQR) age, NT-proBNP, LV ejection
fraction were respectively 59 (41-74), 323pg/ml (58-1960) and 60% (51-66).
64% were men and 12 had an increased in cTnT. TTR gene mutations preva-
lence was 50% for Val30Met. 4 patients were asymptomatic, 6 had only neu-
rologic clinical signs and 26 had echo-LV abnormalities with or without
neurologic disorders. Their median NT-proBNP value were respectively: 33
(19-50), 54 (37-154) and 747 (253;2840). Using received-operator curve,
NTproBNP identified significantly patients with echo-LV abnormalities
(Area : 0.92;(0.83-0.99), p=0.001) with a threshold above 82pg/ml and a sen-
sitivity of 92% and specificity of 90%. Elevated cTnT (superior to 0.01ng/ml)
was only observed in patients combining impairment of LVH and SD or LVH,
SD and FP.
Baseline 3 months 1-2 years End f/u P value
NYHA functional 
class, (%)
< 0,0001
Grade 1 0 31 35 36
Grade 2 43 53 59 57
Grade 3 52 16 6 7
Grade 4 5 0 0 0
Syncope/near-
syncope (%)
76/48 2/2 2/2 2/2 <0,0001
Angina (%) 57 4 4 4 <0,0001
LVOT gradient 
(mmHg)
79±36 20±24 11±15 8±21 <0,0001
SAM (%) 96 38 30 16 <0,0001
LVEF (%) 63,5±7,5 61±7 59±7 56±9 0,05
LVEDD (%) 47±5 NA NA 43±12 0,34
